Delivery Order SPE2DR25D2206-SPE2DR26F9BA9
- Not listed
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens in 0.5 mL single-dose units, valued at $3,065.58. This competitive award represents a firm fixed price delivery order with an ultimate completion date of October 20, 2025. The contract is not set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $2,460 delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens in 0.5 mL doses. The order is non-competitive and utilizes firm fixed pricing under a delivery order contract type, with an ultimate completion date of November 12, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a $4,451.71 delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of November 7, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a $38,195.64 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pens in 0.5 mL quantities. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by September 18, 2025. The contract will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $13,137.57 delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract is set to conclude on October 27, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. As a non-set-aside procurement, the award reflects AmerisourceBergen's continued role as a critical pharmaceutical supplier within the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $6,752.39. This is a firm fixed-price delivery order with an ultimate completion date of November 5, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $20,970.95. This is a firm fixed price delivery order with an ultimate completion date of September 16, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $17,564.19 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within the company's...
- The Defense Logistics Agency awarded a $6,987.59 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pen injections. This is a firm fixed-price contract with an ultimate completion date of September 16, 2025, and represents a non-set-aside award issued through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9BA9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pens in 0.5 mL doses, with a contract value of $20,414.52. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The order is due for completion by November 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999 and extends through December 2026. This comprehensive IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates its established capability as a critical pharmaceutical distributor for the Defense Health Agency and other government healthcare systems, with delivery orders covering diverse therapeutic categories including specialty medications, vaccines, and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.4k | 11/10/25 |